BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: White CW, Kilpatrick LE, Dale N, Abhayawardana RS, Dekkers S, Stocks MJ, Pfleger KDG, Hill SJ. CXCL17 is an endogenous inhibitor of CXCR4 via a novel mechanism of action.. [DOI: 10.1101/2021.07.05.451109] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
Number Citing Articles
1 Hashemi SF, Khorramdelazad H. The cryptic role of CXCL17/CXCR8 axis in the pathogenesis of cancers: a review of the latest evidence. J Cell Commun Signal 2022. [DOI: 10.1007/s12079-022-00699-7] [Reference Citation Analysis]
2 Harms M, Hayn M, Zech F, Kirchhoff F, Münch J. Endogenous Peptide Inhibitors of HIV Entry. Advances in Experimental Medicine and Biology 2022. [DOI: 10.1007/978-981-16-8702-0_5] [Reference Citation Analysis]